Evidence map›Paper›PMID 17634226›Full record

ArticleJournal of virology2007

The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc.

Jianyong Liu, Heather J Martin, Gangling Liao, S Diane Hayward

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers.

0numbers the graph read from it
0cells of the map it votes in
82citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

82 citing papers in PubMed, 131 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Kaposi Sarcoma, a Trifecta of Pathogenic Mechanisms.Diagnostics (Basel, Switzerland) · 2022
    Review
  14. Article
  15. Review
  16. Cellular microRNA-127-3p suppresses oncogenic herpesvirus-induced transformation and tumorigenesis via down-regulation of SKP2.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  17. Review
  18. Metabolic Control by DNA Tumor Virus-Encoded Proteins.Pathogens (Basel, Switzerland) · 2021
    Review
  19. Article
  20. Article

22 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Jianyong LiuViral Oncology Program, Sidney Kimmel Cancer Center, and Department of Pharmacology, Johns Hopkins School of Medicine, Bunting-Blaustein Bldg., CRB308, 1650 Orleans St., Baltimore, MD 21231, USA.
Heather J Martin
Gangling Liao
S Diane Hayward
Sidney Kimmel Cancer Center · USJohns Hopkins University · US

Funding

Role of KSHV in AIDS MalignanciesP01CA113239 · NCI · JOHNS HOPKINS UNIVERSITY · PI NICHOLAS, JOHN · 2006 to 2010
$5.8M
NCI NIH HHS P01 CA113239
6 · The paper itself

Abstract

The Kaposi's sarcoma-associated herpesvirus (KSHV) latency-associated nuclear antigen (LANA) protein is functionally pleiotropic. LANA contributes to KSHV-associated pathogenesis, in part, by increasing entry of cells into S phase through a process that is driven by LANA interaction with the serine-threonine kinase glycogen synthase kinase 3 (GSK-3) and stabilization of beta-catenin. We now show that LANA affects the activity of another protein involved in cell cycle regulation, c-Myc. Sequencing of c-Myc coding sequences revealed that c-Myc in KSHV-positive primary effusion lymphoma (PEL) cell lines is wild type in the N-terminal region that regulates c-Myc protein stability. Despite this, c-Myc in PEL cells is stabilized. In LANA-expressing cells, inactivation of nuclear GSK-3 reduced phosphorylation of c-Myc at Thr58 and contributed to c-Myc stabilization by decreasing c-Myc ubiquitination. Phosphorylation of c-Myc on Ser62 also affects c-Myc stability and function. We now show that LANA increases the level of phosphorylated extracellular signal-regulated kinase 1 (ERK1) and increases ERK phosphorylation of c-Myc on Ser62. LANA also interacted with c-Myc, and c-Myc amino acids 147 to 220 were required for this interaction. LANA (L1006P) retained the ability to bind to c-Myc and activate ERK1, indicating that these events did not require LANA interaction with GSK-3. Thus, LANA stabilizes c-Myc; prevents the phosphorylation of c-Myc at Thr58, an event that promotes Myc-induced apoptosis; and independently stimulates phosphorylation of c-Myc at Ser62, an event that transcriptionally activates c-Myc. LANA-mediated manipulation of c-Myc function is likely to contribute to KSHV-associated tumorigenesis through the induction of c-Myc regulated cellular genes, as well as by the stimulation of cell cycle progression.

Indexed as

Amino Acid SequenceAntigens, ViralCell Line, TumorGlycogen Synthase Kinase 3Herpesvirus 8, HumanHumansMitogen-Activated Protein Kinase 3Molecular Sequence DataNuclear ProteinsPhosphorylationProto-Oncogene Proteins c-mycSarcoma, KaposiSerineThreonineUbiquitinAntigens, ViralGlycogen Synthase Kinase 3latency-associated nuclear antigenMitogen-Activated Protein Kinase 3MYC protein, humanNuclear ProteinsProto-Oncogene Proteins c-mycSerineThreonineUbiquitin

Identifiers

PMID17634226
PMCPMC2045471
OpenAlexW2042974814

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.